📰 Liminal Bioscience News
Page 5 - Liminal Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Liminal Bioscience. Real-time updates on events, politics, business and more.
November 8, 2022
LAVAL, QC and CAMBRIDGE, England, Nov. 8, 2022 /PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third
November 8, 2022
/PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter...
September 1, 2022
LAVAL, QC and CAMBRIDGE, England, Sept. 1, 2022 /PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that it received confirmation
September 1, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that it received confirmation from the Listing...
August 29, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced that...
August 25, 2022
Termination results in anticipated cash savings of $33.1 millionRemoves last of legacy contracts associated with former plasma-derived therapeutics businessLAVAL, QC and CAMBRIDGE, ENGLAND,
August 25, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced today...
August 9, 2022
$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras developmentNet loss from continuing operations of $6.5 million during the quarter ended June 30, 2022
July 21, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of...
July 21, 2022
/PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of...